Background: In the setting of familial melanoma, the presence of atypical nevi, which are the precursors of melanoma, is associated with a nearly 100% risk of developing primary melanoma by age 70. In patients with sporadic melanoma, it is estimated that 40-60% of melanomas develop in contiguous association with atypical nevi. Currently, the only way to prevent atypical nevi from progressing to melanoma is to monitor and excise them as soon as they exhibit changes in their clinical features. Activation of the transcription factor, Stat3, has been linked to abnormal cell growth and transformation as well as to interferon a (IFN-a)-mediated growth suppression in vitro. Materials and Methods: To determine whether IFN-a, used for adjuvant therapy of high-risk, resected melanoma, induces changes in Stat3 in atypical nevi, patients with a clinical history of melanoma who have multiple atypical nevi were treated for 3 months with low-dose IFN-a. Thereupon, the new technology of microscopic spectral imaging and biochemical assays such as electro-
Introduction
Congenital nevi and common acquired nevi, which first appear in early childhood, present in three clinical and histologic patterns-junctional, compound, and dermal. Junctional nevi are collections of normal melanocytes along the basal layer of the epidermis appearing as single cells or junctional nests. In a compound nevus, melanocytes are present in the epidermis and dermis, and when nevus cells disappear from the epidermis, the lesion often loses its pigment and becomes a dermal nevus. Each of these types of nevi is considered benign until the following clinical and histologic features are observed: size .5 mm in diameter, macular surface component, irregular or diffuse borders, variegated pigmentation, continuous proliferation of basal melanocytes, bridging and confluence of the rete ridges, nuclear pleomorphism, and the presence of lymphocytic infiltrate. It is the combination of these features that defines atypical nevi, which are the precursors and risk markers of tumor progression (1, 2) .
For patients with familial melanoma and/or dysplastic nevus syndrome (3), and likewise, for patients who have a clinical history of sporadic melanoma and numerous atypical nevi, the only way to currently prevent these melanocytic lesions from progressing to melanoma is to persistently monitor and resect them at the earliest signs of changes in shape, size, and/or pigmentation. Thus, it would be of great clinical benefit for these patients if one could implement a systemic treatment that, by modulating the molecular, immunologic, histologic, and clinical features of these melanoma precursor lesions, would ultimately lead to their regression.
Interferons (IFNs) are a family of antiviral, antiproliferative, antiangiogenic, immunoregulatory, and cell surface antigen-modulating molecules that are effectively used in the therapy of several human malignancies including hairy-cell leukemia, lymphoma, and Kaposi's sarcoma. In patients with resected melanoma, either with deep primary invasion or lymph node metastases, who are at high risk for relapse, high-dose IFN-a given for 1 year has been shown to benefit relapse-free and overall survival, while patients with resected primary melanoma thicker than 1.5 mm, who had no clinically detectable lymph node metastases, have shown delayed relapse with low-dose IFN-a given for 12 or 18 months. Given the results of these clinical trials, high-and low-dose IFN-a (4-6) are currently used for adjuvant therapy of high-risk, resected melanoma.
Stat proteins, which were first identified by studying early signaling events in IFN-treated cells (7) (8) (9) The degree of architectural and cytologic atypia of each nevus specimen was determined according to established histopathologic criteria (2, 12) . All specimens were diagnosed as nevi exhibiting a moderate or severe degree of histologic atypia.
Immunohistochemistry Snap-frozen nevus sections were analyzed by immunohistochemistry as previously described (12, 13) . Polyclonal antibodies to Stat 1, Stat2, and Stat3 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A polyclonal antibody, recognizing Stat3 protein only when activated by phosphorylation-at Tyr7O5, was obtained from New England Biolabs (Beverly, MA). A mouse IgGI antibody (Tago, Burlingame, CA) was used as an isotype control.
To minimize the possibility that experimental conditions would lead to differences in Stat expression, adjacent nevus sections were cut and probed at the same time with similar concentrations of the respective antibodies.
Microscopic Spectral Imaging Analysis
Nevus sections probed with antibodies to Stat 1, Stat2, and Stat3 and counterstained with hematoxylin were imaged at 20X using a Nikon Eclipse E800 microscope coupled to a Fouriertransform imaging spectrometer (14) (SpectraCube, Applied Spectral Imaging, Carlsbad, CA). The spectral cubes were transferred to a computer where the images were converted from transmission to optical density. Spectra corresponding to the Stat-specific hybridization signals and the hematoxylin-stained nuclei were selected manually. A linear unmixing algorithm, implemented in custom-designed spectral imaging analysis software (15) , was applied to each image to detect the presence and intensity of the immunohistochemical and hematoxylin stains. The output of this algorithm was used to generate pseudocolored images for maximum visibility.
Electrophoretic Mobility Shift Assay Protein extracts (20 ,ug/sample), prepared from snap-frozen sections of atypical nevi and normal skin, were analyzed by gel shifts and supershifts as previously described (16) (17) (18) (19) .
Immunoblot Analysis
Total cell lysates (20 To assess the status of expression and cellular location of Stat 1, Stat2, and Stat3 in atypical nevi before and after systemic low-dose IFN-a treatment, we probed sections of atypical nevi, obtained before and after treatment, with antibodies specific for each of the three proteins.
In the context of immunohistochemical studies, it is often difficult to assess on a cell-bycell basis whether a protein is located in the cytoplasm or the nucleus. This task becomes even more complicated in the case of pigmented lesions, where the melanin of junctional and dermal melanocytes frequently masks the hybridization signal(s). To circumvent these potential problems, we subjected the stained nevus sections to microscopic spectral imaging analysis, which made it possible to visualize the location of the Stats in individual cells.
Spectral imaging, defined as the application of spatially resolved spectroscopic analyses to macroscopic and microscopic samples (1 5,20) , allows a high-resolution spectrum-intensity as a function of wavelength-to be acquired at each pixel in an image. The result is an image cube that contains both spectral and spatial information. Unlike conventional transmittance and fluorescence microscopy, spectral imaging has the ability to generate qualitative and quantitative multiparameter high-resolution images at the single cell level.
As depicted in Figure IA and B, upon staining with a Stat3-specific antibody, tissue sections prepared from atypical nevi obtained before (Fig. LA) and after (Fig. 1B) IFN Figure 2A , two atypical nevi, obtained from a patient before IFN-ca treatment ( Fig. 2A, a and b Figure 2B , document that the Stat3 antibody supershifted major portions of the Stat3/Stat3 homodimer and Stat 1 /Stat3 heterodimer but not the Statl/Statl homodimer in an atypical nevus (Fig. 2B, c) and its surrounding normal skin (Fig. 2B, f) tein extracts of the same nevus (Fig. 2B, a) and adjacent normal skin (Fig. 2B, d) (Fig. 2B, b ) or in its surrounding normal skin (Fig. 2B, e) .
Systemic IFN- (Fig. 3C, a) and its surrounding normal skin (Fig. 3C, c) , both of which were excised before IFN-a treatment. In contrast, an atypical nevus (Fig. 3C, b) and adjacent normal skin (Fig. 3C, d) (23, 24) and cell survival (25) , and that its activation is associated with abnormal cell growth and transformation (26, 27) . In light of these observations, particularly the latter, one may propose a model wherein EGFR activates Statl and Stat3 in atypical nevi which, in turn, leads to StatI and Stat3-induced transcription of genes that play a role in the development of melanoma. Assuming this model is correct, the question then arises: what is the status of these proteins in melanomas evolving within these precursor lesions? To obtain an answer for this question, we are presently investigating whether melanomas in situ, which represent the earliest stage of progression from atypical nevi to melanoma, express EGFR and contain constitutively activated and phosphorylated Statl and Stat3.
A second question that arises with respect to the data presented here is: how does systemic IFN-a treatment lead to Statl and Stat3 inactivation in melanoma precursor lesions? For example, it has been suggested that down-regulation of Stat proteins occurs as a result of their dephosphorylation by protein tyrosine phosphatases (28) . Another proposed mechanism is Stat degradation through ubiquitination pathways (29) . A more recently described third pathway involves blocking of the DNA binding activity of Stats by protein inhibitors of activated Stat (PIAS) (30) . Among the members of the family of PIAS, PIAS3 was found to be a specific inhibitor of Stat3 signaling (30) , while PIAS1 blocked the DNA-binding activity of Statl (31) . In addition, the latter report documented that in vitro, treatment of human Daudi B-cells with IFN-a led to association of PIAS 1 Finally, these investigations establish that it is possible to study gene regulation in atypical nevi despite their small size, and that the nevic cells from these lesions cannot be cultured and propagated in vitro.
